ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBRX ImmunityBio, Inc.

休市中 12-12 16:00:00 EST

2.36

+0.17

+7.76%

盘后2.37

+0.01+0.42%

19:59 EST

最高2.50	最低2.25	成交量2,486万
今开2.29	昨收2.19	日振幅11.42%
总市值23.25亿	流通市值4.58亿	总股本9.85亿
成交额5,926万	换手率12.81%	流通股本1.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBRX","market":"US","secType":"STK","nameCN":"ImmunityBio, Inc.","latestPrice":2.36,"timestamp":1765573200000,"preClose":2.19,"halted":0,"volume":24855981,"hourTrading":{"tag":"盘后","latestPrice":2.37,"preClose":2.36,"latestTime":"19:59 EST","volume":200045,"amount":477071.8149,"timestamp":1765587599081},"delay":0,"floatShares":194000000,"shares":984965179,"eps":-0.415322,"marketStatus":"休市中","change":0.17,"latestTime":"12-12 16:00:00 EST","open":2.29,"high":2.5,"low":2.25,"amount":59261331.628428,"amplitude":0.114155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.415322,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1438056000000,"exchange":"NASDAQ","adjPreClose":2.19,"preHourTrading":{"tag":"盘前","latestPrice":2.3,"preClose":2.19,"latestTime":"09:29 EST","volume":490509,"amount":1116219.1048587,"timestamp":1765549799913},"postHourTrading":{"tag":"盘后","latestPrice":2.37,"preClose":2.36,"latestTime":"19:59 EST","volume":200045,"amount":477071.8149,"timestamp":1765587599081},"volumeRatio":2.750845396426382,"impliedVol":0.926,"impliedVolPercentile":0.244},"requestUrl":"/m/hq/s/IBRX/wiki","defaultTab":"wiki","newsList":[{"id":"1108392616","title":"ImmunityBio获得欧洲药品管理局的条件性市场授权推荐，用于非肌肉侵袭性膀胱癌原位癌的Anktiva®与BCG联合治疗——在欧洲的首次","url":"https://stock-news.laohu8.com/highlight/detail?id=1108392616","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108392616?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:10","pubTimestamp":1765537813,"startTime":"0","endTime":"0","summary":"ImmunityBio获得欧洲药品管理局的条件性市场授权推荐，用于非肌肉侵袭性膀胱癌原位癌的Anktiva®与BCG联合治疗——在欧洲的首次","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"1109214275","title":"受强劲需求推动，ImmunityBio公布单位增长467%及销售额7500万美元，同比增长434%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109214275","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109214275?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:12","pubTimestamp":1762312333,"startTime":"0","endTime":"0","summary":"受强劲需求推动，ImmunityBio公布单位增长467%及销售额7500万美元，同比增长434%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2574413881","title":"Immunitybio, Inc.盘中异动 股价大跌5.10%报2.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574413881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574413881?lang=zh_cn&edition=full","pubTime":"2025-10-10 01:53","pubTimestamp":1760032408,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日01时53分，Immunitybio, Inc.股票出现波动，股价快速跳水5.10%。截至发稿，该股报2.40美元/股，成交量655.121万股，换手率0.69%，振幅5.53%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010015328a4588cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010015328a4588cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1119825800","title":"ImmunityBio的Anktiva®逆转淋巴细胞减少症，延长对检查点疗法耐药的晚期非小细胞肺癌患者总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1119825800","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119825800?lang=zh_cn&edition=full","pubTime":"2025-09-08 20:31","pubTimestamp":1757334672,"startTime":"0","endTime":"0","summary":"ImmunityBio的Anktiva®逆转淋巴细胞减少症，延长对检查点疗法耐药的晚期非小细胞肺癌患者总生存期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1118190780","title":"ImmunityBio, Inc.盘前涨4.9% 实验性癌症疗法初步数据显示良好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1118190780","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118190780?lang=zh_cn&edition=full","pubTime":"2025-08-26 20:40","pubTimestamp":1756212015,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.股价在盘前交易中上涨4.9%，此前该公司实验性癌症治疗方案的初步研究数据显示出令人鼓舞的治疗前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1136784131","title":"初步数据显示：ImmunityBio公司Anktiva®联合NK细胞疗法及Optune Gio®设备治疗复发性胶质母细胞瘤，5名患者中实现100%疾病控制，其中2名患者接近完全缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1136784131","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136784131?lang=zh_cn&edition=full","pubTime":"2025-08-26 20:31","pubTimestamp":1756211489,"startTime":"0","endTime":"0","summary":"初步数据显示：ImmunityBio公司Anktiva®联合NK细胞疗法及Optune Gio®设备治疗复发性胶质母细胞瘤，5名患者中实现100%疾病控制，其中2名患者接近完全缓解","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2558666925","title":"Immunitybio, Inc.盘中异动 快速拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558666925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558666925?lang=zh_cn&edition=full","pubTime":"2025-08-11 22:11","pubTimestamp":1754921514,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日22时11分，Immunitybio, Inc.股票出现波动，股价急速上涨5.33%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081122115494dccfc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081122115494dccfc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2558768681","title":"Immunitybio, Inc.2025财年第二财季实现净利润-92.56百万美元，同比增加31.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558768681","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558768681?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841669,"startTime":"0","endTime":"0","summary":"8月11日，Immunitybio, Inc.公布财报，公告显示公司2025财年第二财季净利润为-92.56百万美元，同比增加31.44%；其中营业收入为26.43百万美元，同比增加2417.14%，每股基本收益为-0.10美元。从资产负债表来看，Immunitybio, Inc.总负债9.72亿美元，其中短期债务7.44百万美元，资产负债比为0.42，流动比率为0.05。机构评级：截至2025年8月11日，当前有5家机构对Immunitybio, Inc.目标价做出预测，其中目标均价为11.40美元，其中最低目标价为5.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000245a6de0782&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000245a6de0782&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX"],"gpt_icon":0},{"id":"2555286200","title":"Immunitybio, Inc.盘中异动 股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555286200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555286200?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:46","pubTimestamp":1753886808,"startTime":"0","endTime":"0","summary":"北京时间2025年07月30日22时46分，Immunitybio, Inc.股票出现异动，股价急速拉升5.08%。截至发稿，该股报2.67美元/股，成交量155.808万股，换手率0.18%，振幅3.39%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730224648a6c9ec98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730224648a6c9ec98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2555964703","title":"Immunitybio, Inc.盘中异动 股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555964703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555964703?lang=zh_cn&edition=full","pubTime":"2025-07-29 00:32","pubTimestamp":1753720327,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日00时32分，Immunitybio, Inc.股票出现波动，股价大幅下跌5.21%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729003207a4681118&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729003207a4681118&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2551199833","title":"Immunitybio, Inc.盘中异动 股价大跌5.17%报2.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551199833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551199833?lang=zh_cn&edition=full","pubTime":"2025-07-16 00:40","pubTimestamp":1752597659,"startTime":"0","endTime":"0","summary":"北京时间2025年07月16日00时40分，Immunitybio, Inc.股票出现异动，股价大幅跳水5.17%。截至发稿，该股报2.75美元/股，成交量363.223万股，换手率0.41%，振幅6.55%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为1.03%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716004100a44cd0de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716004100a44cd0de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2550664655","title":"Immunitybio, Inc.盘中异动 早盘大幅上涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550664655","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550664655?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:42","pubTimestamp":1752068570,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日21时42分，Immunitybio, Inc.股票出现波动，股价大幅上涨5.16%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为1.18%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214250a4407e91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214250a4407e91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2549588905","title":"Immunitybio, Inc.盘中异动 早盘股价大涨6.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549588905","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549588905?lang=zh_cn&edition=full","pubTime":"2025-07-07 21:31","pubTimestamp":1751895102,"startTime":"0","endTime":"0","summary":"北京时间2025年07月07日21时31分，Immunitybio, Inc.股票出现异动，股价大幅上涨6.62%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707213142a43bf636&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707213142a43bf636&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2548848883","title":"Immunitybio, Inc.盘中异动 早盘快速跳水5.11%报2.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548848883","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548848883?lang=zh_cn&edition=full","pubTime":"2025-07-01 23:11","pubTimestamp":1751382669,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日23时11分，Immunitybio, Inc.股票出现波动，股价快速下挫5.11%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701231109a728b6ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701231109a728b6ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2546249649","title":"Immunitybio, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546249649","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546249649?lang=zh_cn&edition=full","pubTime":"2025-06-25 22:11","pubTimestamp":1750860680,"startTime":"0","endTime":"0","summary":"北京时间2025年06月25日22时11分，Immunitybio, Inc.股票出现异动，股价急速下挫5.02%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625221120a71d3428&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625221120a71d3428&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2544599523","title":"Immunitybio, Inc.盘中异动 股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544599523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544599523?lang=zh_cn&edition=full","pubTime":"2025-06-17 22:17","pubTimestamp":1750169821,"startTime":"0","endTime":"0","summary":"北京时间2025年06月17日22时17分，Immunitybio, Inc.股票出现异动，股价快速下挫5.11%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617221701978383db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617221701978383db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":1},{"id":"2543603713","title":"Immunitybio, Inc.盘中异动 快速拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543603713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543603713?lang=zh_cn&edition=full","pubTime":"2025-06-16 21:54","pubTimestamp":1750082050,"startTime":"0","endTime":"0","summary":"北京时间2025年06月16日21时54分，Immunitybio, Inc.股票出现异动，股价快速拉升5.21%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506162154109781f271&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506162154109781f271&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"2518744703","title":"Immunitybio, Inc.2024财年实现净利润-4.14亿美元，同比增加28.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518744703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518744703?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449675,"startTime":"0","endTime":"0","summary":"3月9日，Immunitybio, Inc.公布财报，公告显示公司2024财年净利润为-4.14亿美元，同比增加28.99%；其中营业收入为14.75百万美元，同比增加2271.38%，每股基本收益为-0.59美元。从资产负债表来看，Immunitybio, Inc.总负债8.71亿美元，其中短期债务8.71百万美元，资产负债比为0.44，流动比率为0.04。机构评级：截至2025年3月9日，当前有5家机构对Immunitybio, Inc.目标价做出预测，其中目标均价为11.25美元，其中最低目标价为4.25美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000245abef9883&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000245abef9883&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX"],"gpt_icon":0},{"id":"2516313637","title":"Immunitybio, Inc.盘中异动 早盘急速下跌5.47%报3.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516313637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516313637?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012286,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Immunitybio, Inc.股票出现异动，股价急速跳水5.47%。截至发稿，该股报3.11美元/股，成交量52.7219万股，换手率0.07%，振幅3.95%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Immunitybio, Inc.公司简介：ImmunityBio Inc 是一家临床阶段的综合性生物技术公司，致力于发现，开发和商业化下一代免疫和细胞疗法，以增强天然免疫系统，驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223126abe632ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223126abe632ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1176337306","title":"ImmunityBio 2024年第四季度GAAP每股收益$(0.09)优于预期$(0.20)，销售额$7.55M不及预期$7.82M，拥有$149.8M现金及现金等价物和有价证券","url":"https://stock-news.laohu8.com/highlight/detail?id=1176337306","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176337306?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:40","pubTimestamp":1741005640,"startTime":"0","endTime":"0","summary":"ImmunityBio报告季度每股亏损为$，优于分析师共识预期的$，高出55%。相比去年同期每股亏损$，这是一个74.29%的增长。公司报告季度销售额为755万美元，低于分析师共识预期的782万美元，低了3.39%。以上内容来自Benzinga Earnings专栏，原文如下：ImmunityBio  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 55 percent. This is a 74.29 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.55 million which missed the analyst consensus estimate of $7.82 million by 3.39 percent.  This is a 5.33K per","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ImmunityBio 2024年第四季度GAAP每股收益$(0.09)优于预期$(0.20)，销售额$7.55M不及预期$7.82M，拥有$149.8M现金及现金等价物和有价证券","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.immunitybio.com","stockEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":0.1456},{"period":"3month","weight":-0.0923},{"period":"6month","weight":-0.2313},{"period":"1year","weight":-0.2237},{"period":"ytd","weight":-0.0781}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ImmunityBio, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。公司是一家领先的临床剂型的现成自然杀伤细胞疗法生产商，记忆NK细胞，连同抗体细胞因子融合蛋白、白蛋白结合化学免疫调节剂和疫苗载体的综合平台。通过结合这些NK、巨噬细胞和T细胞激活平台，该公司相信ImmunityBio在免疫治疗领域处于领先地位，具有跨越多种肿瘤类型和传染病的后期临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":0.02541},{"month":2,"riseRate":0.5,"avgChangeRate":0.026818},{"month":3,"riseRate":0.3,"avgChangeRate":-0.083879},{"month":4,"riseRate":0.5,"avgChangeRate":0.021643},{"month":5,"riseRate":0.4,"avgChangeRate":0.054052},{"month":6,"riseRate":0.3,"avgChangeRate":0.132356},{"month":7,"riseRate":0.4,"avgChangeRate":-0.029239},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.110134},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.03348},{"month":10,"riseRate":0.454545,"avgChangeRate":0.029893},{"month":11,"riseRate":0.636364,"avgChangeRate":0.121867},{"month":12,"riseRate":0.363636,"avgChangeRate":0.063589}],"exchange":"NASDAQ","name":"ImmunityBio, Inc.","nameEN":"ImmunityBio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ImmunityBio, Inc.,IBRX,ImmunityBio, Inc.股票,ImmunityBio, Inc.股票老虎,ImmunityBio, Inc.股票老虎国际,ImmunityBio, Inc.行情,ImmunityBio, Inc.股票行情,ImmunityBio, Inc.股价,ImmunityBio, Inc.股市,ImmunityBio, Inc.股票价格,ImmunityBio, Inc.股票交易,ImmunityBio, Inc.股票购买,ImmunityBio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}